Suppr超能文献

低细胞角蛋白19表达的乳腺癌前哨淋巴结转移一步核酸扩增检测假阴性结果1例

A Case of False-Negative Results in the One-Step Nucleic Acid Amplification Assay for Sentinel Lymph Node Metastasis in Breast Cancer with Low Cytokeratin 19 Expression.

作者信息

Koyanagi Ai, Kakumoto Akinari, Kuroda Hajime, Baba Shogo, Koketsu Mami, Harada Oi, Kato Yasutaka, Nishihara Hiroshi, Kawami Hiroyuki

机构信息

Department of Diagnostic Pathology, Tokyo Women's Medical University Adachi Medical Center, Adachi-Ku, Japan.

Department of Pathology and Genetics, Laboratory of Cancer Medical Science, Hokuto Hospital, Obihiro, Japan.

出版信息

Case Rep Oncol. 2025 Jul 2;18(1):1074-1080. doi: 10.1159/000546995. eCollection 2025 Jan-Dec.

Abstract

INTRODUCTION

One-step nucleic acid amplification (OSNA) for the analysis of sentinel lymph nodes is now widely used as a reliable tool for the intraoperative diagnosis of breast cancer metastasis based on the quantification of CK19 mRNA. However, discrepancies have been noted between the molecular diagnosis and histological evaluation, potentially due to differences in tissue sampling or technical limitations. Furthermore, false-negative results may occur when target mRNA expression is reduced.

CASE PRESENTATION

We herein describe a 45-year-old female patient who underwent breast-conserving surgery. The final pathological stage after surgery was pT2N1aM0 (stage IIB), hormone receptor positive (HER2: 1+). An OSNA analysis of two sentinel lymph nodes revealed no metastasis, whereas touch imprint cytology of one of the lymph nodes was positive. Immunohistochemistry of the primary tumor showed a mixture of extensive CK19-negative and focal CK19-positive lesions. A genetic analysis of the CK19-negative lesion detected mutations and abnormalities, including the amplification, deletion, deletion, deletion, deletion, and mutations in , , , , and . Of these, tumor heterogeneity and genetic alterations, including mutations in , , and , in the CK19-negative lesion were hypothesized to suppress CK19 expression.

CONCLUSION

False-negative results are more likely to occur for CK19-negative breast cancer, emphasizing the importance of incorporating complementary diagnostic methods, such as touch imprint cytology and different molecular markers. A multifaceted diagnostic approach is crucial for ensuring accurate staging and appropriate treatment planning.

摘要

引言

基于细胞角蛋白19(CK19)信使核糖核酸(mRNA)定量分析的前哨淋巴结一步核酸扩增(OSNA),如今已被广泛用作乳腺癌转移术中诊断的可靠工具。然而,分子诊断与组织学评估之间存在差异,这可能是由于组织采样差异或技术限制所致。此外,当靶mRNA表达降低时可能会出现假阴性结果。

病例报告

我们在此描述一名45岁接受保乳手术的女性患者。术后最终病理分期为pT2N1aM0(IIB期),激素受体阳性(人表皮生长因子受体2:1+)。对两个前哨淋巴结进行的OSNA分析显示无转移,而其中一个淋巴结的印片细胞学检查呈阳性。原发肿瘤的免疫组织化学显示广泛的CK19阴性和局灶性CK19阳性病变混合存在。对CK19阴性病变进行的基因分析检测到突变和异常,包括 、 、 、 、 的扩增、缺失、缺失、缺失、缺失以及 、 、 中的突变。其中,推测CK19阴性病变中的肿瘤异质性和基因改变,包括 、 、 中的突变,抑制了CK19表达。

结论

CK19阴性乳腺癌更易出现假阴性结果,这凸显了采用互补诊断方法(如印片细胞学检查和不同分子标志物)的重要性。多方面的诊断方法对于确保准确分期和恰当的治疗规划至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7313/12331226/1eec7976887e/cro-2025-0018-0001-546995_F01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验